Status:
UNKNOWN
Repeated Methotrexate for Proliferative Vitreoretinopathy Grade C
Lead Sponsor:
Shahid Beheshti University of Medical Sciences
Conditions:
Proliferative Vitreoretinopathy
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
This multicenter randomized clinical trial evaluates the effect of multiple intra-silicone oil injections of methotrexate (MTX) on rhegmatogenous retinal detachment (RRD) with grade C proliferative vi...
Eligibility Criteria
Inclusion
- Rhegmatogenous retinal detachment with proliferative vitreoretinopathy grade C
Exclusion
- Age of under 18 years old
- Pregnancy
- Glaucoma
- Macular disorders
- Diabetic retinopathy
- Retinal vascular occlusion
- History of penetrating ocular trauma
- Giant retinal tear
- Chronic uveitis
- History of intraocular steroid injection
Key Trial Info
Start Date :
August 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2021
Estimated Enrollment :
74 Patients enrolled
Trial Details
Trial ID
NCT04482543
Start Date
August 1 2020
End Date
September 1 2021
Last Update
July 22 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ophthalmic Research Center
Tehran, Iran